|
WO2021023274A1
|
|
HUMANIZED ANTI-TNFα ANTIBODY AND USE THEREOF
|
|
WO2021018035A1
|
|
Humanized anti-il17a antibody and use thereof
|
|
WO2021013207A1
|
|
Multivariable dosing method for use in treating high-egfr expression cancer
|
|
WO2021013077A1
|
|
Chimeric human papillomavirus type 58 l1 protein
|
|
WO2021013069A1
|
|
Chimeric human papillomavirus type 11 l1 protein
|
|
WO2021013070A1
|
|
Chimeric human papillomavirus 35 type l1 protein
|
|
WO2021013071A1
|
|
Polyvalent immunogenicity composition for human papillomavirus
|
|
WO2021013073A1
|
|
Chimeric papillomavirus l1 protein
|
|
WO2021013072A1
|
|
Chimeric human papillomavirus type 39 l1 protein
|
|
WO2021013078A1
|
|
Chimeric human papilloma virus 52 type l1 protein
|
|
WO2021013075A1
|
|
Chimeric human papillomavirus type 18 l1 protein
|
|
WO2021013080A1
|
|
Humanized anti-vegf monoclonal antibody
|
|
WO2021013061A1
|
|
Humanized anti-vegfr2 antibody and application thereof
|
|
WO2021013079A1
|
|
Chimeric human papillomavirus 56-type l1 protein
|
|
WO2021013064A1
|
|
Humanized vegfr2 antibody and application thereof
|
|
WO2021013076A1
|
|
Chimeric human papillomavirus type 45 l1 protein
|
|
WO2021013062A1
|
|
Chimeric human papillomavirus type 31 l1 protein
|
|
WO2021013065A1
|
|
Humanized anti-vegf fab antibody fragment and use thereof
|
|
WO2021013067A1
|
|
Chimeric human papillomavirus type 6 l1 protein
|
|
WO2021013063A1
|
|
Chimeric human papillomavirus type 16 l1 protein
|
